Aptevo Therapeutics (APVO) CEO pay: $1.3M actually paid in FY2025
$APVO · Aptevo Therapeutics Inc.Data through FY2025 — latest proxy filed 2026-07-31, checked for new filings 2026-08-21. Every number links to its source.
0.3× the tracked-company median CEO pay ($3.9M).
Pay vs. Performance (Compensation Actually Paid)
What the CEO was actually paid, by fiscal year
What $100 invested was worth, company vs peer group
Pay-vs-Performance table
| FY | CEO pay on paper | CEO pay actually earned | Other top execs (avg) | Value of $100 invested since FY2022 | Same, peer group since FY2022 | Net income |
|---|---|---|---|---|---|---|
| 2025 | $1.3M | $1.3M | $960,054 | — | — | — |
| 2024 | $846,337 | $837,486 | $690,434 | $0.03 | — | -$24.1M |
| 2023 | $916,403 | $809,956 | $574,811 | $0.49 | — | -$17.4M |
| 2022 | $1.2M | $786,510 | $662,672 | — | — | $8.0M |
Frequently asked
How much did the APVO CEO make in 2025?
$1,281,666 in Compensation Actually Paid (CAP) as Aptevo Therapeutics Inc.'s CEO (the filing reports this year's PEO pay without tagging which named executive it belongs to), updated 2026-07-31.
What is pay vs. performance (PvP)?
An SEC disclosure (Item 402(v), required since FY2022) linking named-executive pay to company total shareholder return (TSR) over up to 5 years.
What is Compensation Actually Paid (CAP)?
CAP starts from the Summary Compensation Table total and adjusts equity awards to fair value as of each year-end/vesting date, rather than grant-date value — see the glossary entry for the full walk-through.
Also on APVO: SEC & DOJ enforcement actions · CEO track-record ranking · Glossary